Aspirin and Antiplatelet Drugs in the Prevention of Cardiovascular Complications of Diabetes

  • Alberto Zanchetti

Keywords: Aspirin, antiplatelet drugs, myocardial infarction, stroke, bleeding.


Antiplatelet Therapy Antiplatelet Drug Major Cardiovascular Event Early Treatment Diabetic Retinopathy Study Multiple Risk Factor Intervention Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Stamler J, Vaccaro O, Neaton JD, et al. Diabtes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434–444.CrossRefPubMedGoogle Scholar
  2. 2.
    Zanchetti A, Hansson L, Dahlöf B, et al. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. J Hypertens 2001;19:1149–59.CrossRefPubMedGoogle Scholar
  3. 3.
    Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Arch Intern Med 2005;165:1410–1419.CrossRefGoogle Scholar
  4. 4.
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). JAMA 2001;285:2486–2497.Google Scholar
  5. 5.
    Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71–86.CrossRefGoogle Scholar
  6. 6.
    Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81–106.Google Scholar
  7. 7.
    Early Treatment Diabetic Retinopathy Study Report 14. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. JAMA 1992;268:1292–1300.CrossRefGoogle Scholar
  8. 8.
    Early Treatment Diabetic Retinopathy Study (ETDRS) Research Group: Effects of aspirin treatment on diabetic retinopathy: ETDRS report number 8. Ophthalmology.1991;98(Suppl.):757–765.Google Scholar
  9. 9.
    Peto R. Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 1988;296:313–316.CrossRefPubMedGoogle Scholar
  10. 10.
    Steering Committee of the Physicians' Health Study Research Group. Final Report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129–135.CrossRefGoogle Scholar
  11. 11.
    The Medical Research Council's General Practice Research Framework. Thrombosis Prevention Trial: randomised trial of low-intensity oral anticoagulant with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998;351:233–241.CrossRefGoogle Scholar
  12. 12.
    Meade TW, Brennan PJ on behalf of the MRC General Practice Research Framework. Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ 2000;321:13–17.CrossRefPubMedGoogle Scholar
  13. 13.
    Hansson L, Zanchetti A, Carruthers SG et al for the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755–1762.CrossRefPubMedGoogle Scholar
  14. 14.
    Zanchetti A, Hansson L, Dahlöf B, et al. Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk. J Hypertens 2002;20:2301–2307.CrossRefPubMedGoogle Scholar
  15. 15.
    Collaborative Group of the Primary Prevention Project (PPP). Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001;357:89–95.CrossRefGoogle Scholar
  16. 16.
    Ridker PJ, Cook NR, Lee IM. et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Eng J Med 2005;352:1293–1304.CrossRefGoogle Scholar
  17. 17.
    Chew EY, Klein ML, Murphy RP, et al.Early Treatment Diabetic Retinopathy Study Research Group. Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Arch Ophthalmol 1995;113:52–55.PubMedGoogle Scholar
  18. 18.
    Schulzer M, Mancini GBJ. “Unqualified success” and “unmitigated failure”: number-needed-to-treat-related concepts for assessing treatment efficacy in the presence of treatment-induced adverse effects. Int J Epidemiol 1996;25:704–712.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Alberto Zanchetti
    • 1
  1. 1.Centro Interuniversitario di Fisiologia Clinica e IpertensioneUniversità di Milano and Istituto Auxologico Italiano, Ospedale MaggioreItaly

Personalised recommendations